HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Robert M. Mentzer, Jr Claus Bartels Steven Boyce Gerald D. Buckberg Axel Haverich John Knight Philippe Menasché Lars Thulin Richard D. Weisel Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mentzer, R. M. Search for Related Content PubMed PubMed Citation Articles by Mentzer, R. M., Jr Related Collections Myocardial protection

---

Original Articles: Adult Cardiac

Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study

Accepted for publication October 15, 2007.

^_* Address correspondence to Dr Mentzer, Wayne State University School of Medicine, 540 East Canfield, 1241 Scott Hall, Detroit, MI 48201 (Email: rmentzer{at}med.wayne.edu).

Background: The EXPEDITION study addressed the efficacy and safety of inhibiting the sodium hydrogen exchanger isoform-1 (NHE-1) by cariporide in the prevention of death or myocardial infarction (MI) in patients undergoing coronary artery bypass graft surgery. The premise was that inhibition of NHE-1 limits intracellcular Na accumulation and thereby limits Na/Ca-exchanger–mediated calcium overload to reduce infarct size.

Methods: High-risk coronary artery bypass graft surgery patients (n = 5,761) were randomly allocated to receive either intravenous cariporide (180 mg in a 1-hour preoperative loading dose, then 40 mg per hour over 24 hours and 20 mg per hour over the subsequent 24 hours) or placebo. The primary composite endpoint of death or MI was assessed at 5 days, and patients were followed for as long as 6 months.

Results: At 5 days, the incidence of death or MI was reduced from 20.3% in the placebo group to 16.6% in the treatment group (p = 0.0002). Paradoxically, MI alone declined from 18.9% in the placebo group to 14.4% in the treatment group (p = 0.000005), while mortality alone increased from 1.5% in the placebo group to 2.2% with cariporide (p = 0.02). The increase in mortality was associated with an increase in cerebrovascular events. Unlike the salutary effects that were maintained at 6 months, the difference in mortality at 6 months was not significant.

Conclusions: The EXPEDITION study is the first phase III myocardial protection trial in which the primary endpoint was achieved and proof of concept demonstrated. As a result of increased mortality associated with an increase in cerebrovascular events, it is unlikely that cariporide will be used clinically. The findings suggest that sodium hydrogen exchanger isoform-1 inhibition holds promise for a new class of drugs that could significantly reduce myocardial injury associated with ischemia-reperfusion injury.

This article has been cited by other articles:

				L. D. Hillis, P. K. Smith, J. L. Anderson, J. A. Bittl, C. R. Bridges, J. G. Byrne, J. E. Cigarroa, V. J. DiSesa, L. F. Hiratzka, A. M. Hutter Jr, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., December 6, 2011; 58(24): e123 - e210. [Full Text] [PDF]

				Writing Committee Members, L. D. Hillis, P. K. Smith, J. L. Anderson, J. A. Bittl, C. R. Bridges, J. G. Byrne, J. E. Cigarroa, V. J. DiSesa, L. F. Hiratzka, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation, December 6, 2011; 124(23): e652 - e735. [Full Text] [PDF]

				O. J. Liakopoulos, N. Hristov, G. D. Buckberg, J. Triana, G. Trummer, and B. S. Allen Resuscitation after prolonged cardiac arrest: effects of cardiopulmonary bypass and sodium-hydrogen exchange inhibition on myocardial and neurological recovery Eur J Cardiothorac Surg, October 1, 2011; 40(4): 978 - 984. [Abstract] [Full Text] [PDF]

				R. Vander Heide Clinically Useful Cardioprotection: Ischemic Preconditioning Then and Now Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2011; 16(3-4): 251 - 254. [Abstract] [PDF]

				R. M. Mentzer Jr Myocardial Protection in Heart Surgery Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2011; 16(3-4): 290 - 297. [Abstract] [PDF]

				P. E. Morgan, M. V. Correa, I. L. Ennis, A. A. Diez, N. G. Perez, and H. E. Cingolani Silencing of sodium/hydrogen exchanger in the heart by direct injection of naked siRNA J Appl Physiol, August 1, 2011; 111(2): 566 - 572. [Abstract] [Full Text] [PDF]

				T. J. Pegg, Z. Maunsell, T. D. Karamitsos, R. P. Taylor, T. James, J. M. Francis, D. P. Taggart, H. White, S. Neubauer, and J. B. Selvanayagam Utility of cardiac biomarkers for the diagnosis of type V myocardial infarction after coronary artery bypass grafting: insights from serial cardiac MRI Heart, May 15, 2011; 97(10): 810 - 816. [Abstract] [Full Text] [PDF]

				M. C. Villa-Abrille, E. Cingolani, H. E. Cingolani, and B. V. Alvarez Silencing of cardiac mitochondrial NHE1 prevents mitochondrial permeability transition pore opening Am J Physiol Heart Circ Physiol, April 1, 2011; 300(4): H1237 - H1251. [Abstract] [Full Text] [PDF]

				M. J. Domanski, K. Mahaffey, V. Hasselblad, S. J. Brener, P. K. Smith, G. Hillis, M. Engoren, J. H. Alexander, J. H. Levy, B. R. Chaitman, et al. Association of Myocardial Enzyme Elevation and Survival Following Coronary Artery Bypass Graft Surgery JAMA, February 9, 2011; 305(6): 585 - 591. [Abstract] [Full Text] [PDF]

				M.A. H. Talukder, J. L. Zweier, and M. Periasamy Targeting calcium transport in ischaemic heart disease Cardiovasc Res, December 1, 2009; 84(3): 345 - 352. [Abstract] [Full Text] [PDF]

				J. Inserte, J. A. Barrabes, V. Hernando, and D. Garcia-Dorado Orphan targets for reperfusion injury Cardiovasc Res, July 15, 2009; 83(2): 169 - 178. [Abstract] [Full Text] [PDF]

				V. Venugopal, A. Ludman, D. M. Yellon, and D. J. Hausenloy 'Conditioning' the heart during surgery Eur J Cardiothorac Surg, June 1, 2009; 35(6): 977 - 987. [Abstract] [Full Text] [PDF]

				A.-D. Andersen, K. A. Poulsen, I. H. Lambert, and S. F. Pedersen HL-1 mouse cardiomyocyte injury and death after simulated ischemia and reperfusion: roles of pH, Ca2+-independent phospholipase A2, and Na+/H+ exchange Am J Physiol Cell Physiol, May 1, 2009; 296(5): C1227 - C1242. [Abstract] [Full Text] [PDF]

				S. E. McAllister, M. A. Moses, K. Jindal, H. Ashrafpour, N. J. Cahoon, N. Huang, P. C. Neligan, C. R. Forrest, J. E. Lipa, and C. Y. Pang Na+/H+ exchange inhibitor cariporide attenuates skeletal muscle infarction when administered before ischemia or reperfusion J Appl Physiol, January 1, 2009; 106(1): 20 - 28. [Abstract] [Full Text] [PDF]

				J. R. Schelling and B. G. Abu Jawdeh Regulation of cell survival by Na+/H+ exchanger-1 Am J Physiol Renal Physiol, September 1, 2008; 295(3): F625 - F632. [Abstract] [Full Text] [PDF]